Home/Molecular Partners/Laura Jeanbart, Ph.D.
LJ

Laura Jeanbart, Ph.D.

Head of Portfolio Management and Corporate Communications

Molecular Partners

Therapeutic Areas

Molecular Partners Pipeline

DrugIndicationPhase
MP0533Acute Myeloid Leukemia (AML)Phase 1/2a
MP0317Solid TumorsPhase 1
MP0712Small Cell Lung Cancer & Neuroendocrine CancersPreclinical
Switch-DARPin PlatformVarious Oncology TargetsDiscovery/Preclinical
Radio-DARPin PlatformVarious Oncology TargetsDiscovery/Preclinical